ClearPoint Neuro combines standout revenue growth and strong price momentum with deteriorating earnings execution, sub-floor business quality, and bearish insider selling, leaving the position sized at essentially zero despite double-digit theoretical upside to the analyst target.
Thesis pillars
- Industry Leading Revenue Growth→Stable
- Deteriorating Earnings Execution→Stable
- Overbought Momentum Without Clear Edge→Stable
- +2 more pillars — see the Why tab for full reasoning
ClearPoint Neuro Inc. (CLPT) Stock Analysis
Healthcare · Medical Devices
Sell if holding. Engine safety override at $17.50: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 2.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 4.50; Below-average business quality.
ClearPoint Neuro is a commercial-stage medical device company that develops MRI-guided and operating-room neurosurgical systems, led by its ClearPoint system for deep brain stimulation, biopsy, laser ablation and drug infusion procedures, plus consulting and preclinical services... Read more
Sell if holding. Engine safety override at $17.50: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 2.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 4.50; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.0/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 35d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About ClearPoint Neuro Inc.
About ClearPoint Neuro Inc.
ClearPoint Neuro's five largest hospital customers accounted for approximately 21% of its neurosurgery navigation disposable product revenue in 2025, while the ClearPoint system, IRRAflow system (added through the 2025 acquisition of IRRAS), and ClearPoint Prism laser therapy system together span functional neurosurgery, neurocritical care, and intracranial drug delivery. The company operates two integrated businesses: medical devices for neurosurgical and neurocritical care applications, and consulting and preclinical services for biologics and drug delivery partners.
Neurosurgical device revenue is built on a razor-and-blades model: reusable ClearPoint hardware and IRRAflow control units are placed in hospitals at low margin to generate recurring, higher-margin sales of disposable components such as SmartFrame trajectory devices and IRRAflow catheters. The biologics and drug delivery business supports more than 60 pharma, biotech, and contract research partners evaluating gene and cell therapy delivery into the brain, generating revenue from cannula sales, preclinical studies, and consulting; PTC Therapeutics, whose CEO sits on ClearPoint's board, accounted for approximately 15% of that segment's 2025 revenue under a 2019 supply agreement. Manufacturing runs through the company's Carlsbad and San Diego, California facilities, assembling components sourced largely from single-source third-party suppliers, while the ClearPoint Prism Neuro Laser Therapy System is manufactured exclusively by development partner CLS. Competing DBS systems come from Medtronic, Boston Scientific and Abbott, and competing laser ablation systems from Medtronic's Visualase and Monteris Medical's NeuroBlate.
Show full overview
ClearPoint's own disclosures flag concentration on both the revenue and supply sides: the top five hospital customers represent about 21% of neurosurgery navigation disposable revenue, and PTC Therapeutics alone made up roughly 15% of biologics and drug delivery revenue in 2025, a relationship complicated by PTC's CEO also serving as a ClearPoint director. On the supply side, the company sources most custom ClearPoint components from single-source suppliers and relies exclusively on development partner CLS to manufacture the Prism laser system, meaning a single manufacturing disruption at CLS could halt that product line entirely, notwithstanding ClearPoint's stated belief that alternative sources exist for most other components.
See also: Healthcare · Medical Devices
From ClearPoint Neuro Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
6 floor-breakers·1 ceiling hit
Volatile — 10.1% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -71.6%. Quality floor flags this regardless of sector context.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $17.50: Quality below floor (2.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10 and A.R:R 2.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 4.50; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $16.08. Score 5.0/10, moderate confidence.
Take-profit target: $24.08 (+39.3% upside). Prior stop was $16.08. Stop-loss: $16.08.
Quality below floor (2.9 < 4.0).
ClearPoint Neuro Inc. trades at a P/E of N/A (forward -19.1). TrendMatrix value score: 5.9/10. Verdict: Sell.
9 analysts cover CLPT with a consensus score of 4.2/5. Average price target: $28.
What does ClearPoint Neuro Inc. do?ClearPoint Neuro is a commercial-stage medical device company that develops MRI-guided and operating-room neurosurgical...
ClearPoint Neuro is a commercial-stage medical device company that develops MRI-guided and operating-room neurosurgical systems, led by its ClearPoint system for deep brain stimulation, biopsy, laser ablation and drug infusion procedures, plus consulting and preclinical services for pharmaceutical partners developing brain-targeted gene and cell therapies. Its 2025 acquisition of IRRAS added the IRRAflow intracranial fluid management system for neurocritical care; revenue is concentrated among a small number of hospital sites and drug-delivery partners, including PTC Therapeutics, which accoun